Skip to main content

Table 4 Number and proportion of patients affected by adverse events

From: Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)

 

All subjects (n = 23)

Low dose (N = 13)

High dose (N = 10)

Number (proportion) of patients with serious adverse events

7 (30.4%)

4/13 (30.7%)

3/10 (30%)

Total number of SAE/SAR

10

8

2

Number (proportion) of patients with non-serious adverse events

23 (100%)

13 (100%)

10 (100%)

Total number of non-serious adverse events

93

54

39

Total number (proportion) of non-serious infections

38 (40.8%)

21 (38.8%)

17 (43.5%)

  1. SAE severe adverse event, SAR severe adverse reaction